| Literature DB >> 33235092 |
Fengli Song1, Ziling Liao2, Tong Li1, Ning Kang1, Zhiming Li2, Shufang Fan3, Fengzhi Liu2.
Abstract
Radiodermatitis is a common side effect of radiotherapy, but currently there is no standard treatment for its prevention. This study aimed to observe the effect of topical application of a paste based on traditional Chinese medicine, Jiawei Simiao Yongan Gao, on radiodermatitis caused by radiotherapy for patients with head and neck cancer.This was a retrospective cohort study of 40 patients with head and neck cancer evaluated during their radiotherapy. Of these, 20 patients were treated with Jiawei Simiao Yongan Gao on the irradiated skin from the beginning of radiotherapy (JSY group). The other 20 patients were given standard nursing (standard group). Acute skin reactions were classified according to the radiation-induced skin reaction assessment scale (RISRAS) and American radiation therapy oncology group (RTOG) acute toxicity grading criteria every 2 weeks, and adverse effects were recorded until the end of the radiotherapy.The two groups showed differences in severity of radiodermatitis. At 0 to 30 Gy, the skin reactions were similar in the two groups, while above 40 Gy the skin reactions were significantly lower grade in the JSY group (P < .05). At 0 to 20 Gy, there was no statistical significance (P > .05); but above 30 Gy they were lower in the JSY group (P < .05).Jiawei Simiao Yongan Gao effectively alleviated acute radiodermatitis caused by radiotherapy of head and neck cancer patients compared with standard nursing.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33235092 PMCID: PMC7710264 DOI: 10.1097/MD.0000000000023318
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.889
Scoring the patient's subjective symptoms according to the radiation-induced skin reaction assessment scale (RISRAS).
| Grade of symptom as assessed by the patient | ||||
| Symptom | Not at all | A bit | Some | Very |
| Do you feel any tension, discomfort, or pain in the skin of the radiation region? | 0 | 1 | 2 | 3 |
| Do you feel itchy at the radiation region? | 0 | 1 | 2 | 3 |
| Do you feel burning at the radiation region? | 0 | 1 | 2 | 3 |
| How much do you think the skin reaction caused by radiotherapy affects your daily activities? | 0 | 1 | 2 | 3 |
Clinico-demographic characteristics of the patients.
| Clinical and demographic features | JSY group (n = 20) | Standard group (n = 20) | |
| Age (years) | 58.20 ± 12.73 | 56.85 ± 12.47 | .737 |
| Sex | |||
| male | 13 (65%) | 12 (60%) | 1.000 |
| female | 7 (35%) | 8 (40%) | |
| Tumor localization | |||
| Nasopharyngeal | 10 (50%) | 8 (40%) | .917 |
| Hypopharyngeal | 3 (15%) | 4 (20%) | |
| Oropharyngeal | 3 (15%) | 4 (20%) | |
| Laryngeal | 4 (20%) | 4 (20%) | |
| Clinical stage | |||
| III | 16 (80%) | 15 (55%) | 1.000 |
| IV A | 4 (20%) | 5 (25%) | |
| Planning target Volume 1 | 67.19 ± 1.71 | 67.26 ± 1.69 | .901 |
| Planning target Volume 2 | 57.01 ± 1.45 | 56.73 ± 1.22 | .572 |
Figure 1Graph representing the proportion of dermatitis as monitored by the radiation therapy oncology group (RTOG) acute radiation toxicity scoring system. T on the x-axis represents the time after radiotherapy started. The y-axis represents the percentage of cases.
Figure 2Graph showing the sum of the radiation-induced skin reaction assessment scale (RISRAS) scores. The time after the start of radiotherapy is shown as T on the x-axis, the y-axis shows the sum of RISRAS scores.
Sum of radiodermatitis grade between the two groups.
| JSY group (n = 20) | Standard group (n = 20) | ||||||||
| Grade 1 | Grade 2 | Grade 3 | Total | Grade 1 | Grade 2 | Grade 3 | Total | ||
| T4 | 1 (5%) | 0 | 0 | 1 (5%) | 4 (20%) | 0 | 0 | 4 (20%) | |
| T6 | 3 (15%) | 0 | 0 | 3 | 6 (30%) | 0 | 0 | 6 (30%) | |
| T8 | 14 (70%) | 1 (5%) | 0 | 15 (75%) | 12 (60%) | 8 (40%) | 0 | 20 (100%) | .048 |
| T10 | 18 (90%) | 2 (10%) | 0 | 20 (100%) | 11 (55%) | 9 (45%) | 0 | 20 (100%) | .031 |
| T12 | 18 (90%) | 2 (10%) | 0 | 20 (100%) | 11 (55%) | 6 (30%) | 3 (15%) | 20 (100%) | .040 |
| T14 | 15 (75%) | 5 (25%) | 0 | 20 (100%) | 8 (40%) | 9 (45%) | 3 (15%) | 20 (100%) | .037 |